Search
Filter Results
Displaying 201–210 of 373 results for “coins free fc 26 Visit Buyfc26coins.com Nopeat päivitykset uusista tarjouksista..bWOV”
-
Sep 1, 2023
Eye on the Cure Podcast | Episode 52: Brendan Creemer
Eye on the CureSeptember 1, 2023. Brendan Creemer talks to host Ben Shaberman about how he is taking on the diagnosis of Usher syndrome 1F by dedicating his education and career to becoming a researcher for retinal disease treatments and cures.
-
Aug 18, 2023
Eye on the Cure Podcast | Episode 51: Artur Cideciyan, PhD
Eye on the CureAugust 18, 2023. Artur Cideciyan, PhD, one of the world’s foremost authorities in measuring vision and structural changes in people with retinal diseases, talks with host Ben Shaberman about current imaging tools, functional tests, and his experience as an investigator in several prominent clinical trials at the University of Pennsylvania, Scheie Eye Institute.
-
Jul 21, 2023
Eye on the Cure Podcast | Episode 50: Rachel Huckfeldt, MD, PhD
Eye on the CureJuly 21, 2023. Rachel Huckfeldt, MD, PhD, a clinical researcher and assistant professor of ophthalmology at Mass Eye and Ear, talks with host Ben Shaberman about caring for patients with inherited retinal diseases (IRD), the challenges and opportunities with clinical trials, and the educational and professional journey that led her to the IRD research field.
-
Jul 10, 2023
Blind Author with Usher Syndrome Ignites the Literary World
Beacon StoriesAt the age of 22, Michael Garrigan received a life-changing diagnosis of Usher syndrome type 2. His vision gradually deteriorated over the years, and by the age of 45, he faced the reality of being legally blind. Determined to share his story and shed light on the capacity to triumph over darkness, Michael penned a remarkable memoir, “Ushered Out of Darkness,” in which he invites readers into his most vulnerable life moments and victories.
-
Jun 30, 2023
Eye on the Cure Podcast | Episode 49: Alex Cohen, PhD
Eye on the CureJune 30, 2023. Alex Cohen, PhD, a marketing professor with retinitis pigmentosa, talks with host Ben Shaberman about his career in the hospitality industry and launch of Accessible Pharmacy, a comprehensive pharmacy service for people with vision loss.
-
DiseaseGeographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive vision loss.
-
Jun 16, 2023
Eye on the Cure Podcast | Episode 48: Jami Kern, PhD
Eye on the CureJune 16, 2023. Jami Kern, PhD, chief clinical officer at Nacuity Pharmaceuticals, talks with host Ben Shaberman about NACA, the company’s emerging gene-agnostic therapy for Usher syndrome and retinitis pigmentosa in a Phase 2 clinical trial in Australia. Their conversation includes a discussion about oxidative stress, which NACA is designed to mitigate, and timing for the efficacy readout from the Phase 2 study.
-
Jun 2, 2023
Eye on the Cure Podcast | Episode 47: Kari Branham
Eye on the CureJune 2, 2023. Kari Branham, a genetic counselor with Kellog Eye Center at the University of Michigan, talks to host Ben Shaberman about a variety of topics related to genetic testing and counseling for people with inherited retinal diseases. Their conversation includes discussion of: common misconceptions about genetic testing, variants of unknown significance, when re-testing makes sense, and when and if family members should be tested.
-
May 23, 2023
Summary of the Eighth Annual Retinal Cell & Gene Therapy Innovation Summit 2023
Research NewsThe Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
-
May 19, 2023
Eye on the Cure Podcast | Episode 46: Aaron Osborne, MD
Eye on the CureMay 19, 2023. Aaron Osborne, MD, chief medical officer and chief development officer at Nanoscope Therapeutics, talks about vision restoration in clinical trials of the company’s optogenetic therapy for people with advanced vision loss from retinitis pigmentosa and Stargardt disease.